Therapeutic Drug Monitoring in Tuberculosis: What a Pulmonologist Must Know?

Read full text Summarise with VIRAT
Authors: Rohit Kumar, Ruchi Girotra, Sagar Sharma
Cited by: 0
References: 4

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Case sCenarioA 17-year-old immunocompetent female presented with prolonged pyrexia of unknown origin and constitutional symptoms, including fatigue and night sweats, for 1 year.She was initiated on first-line ATT based on clinical features, radiological evidence of mediastinal lymphadenopathy, and cytopathology demonstrating necrotizing granulomatous inflammation on endobronchial ultrasound-guided transbronchial needle aspiration.After 8 months of ATT, she continued to have a persistent fever.Repeat imaging revealed unresolved mediastinal lymphadenopathy.Review of her treatment history confirmed optimal weight-based dosing and adherence to introduCtion Since the introduction of streptomycin in 1945, the treatment of both drug-susceptible tuberculosis (DS-TB) and drug-resistant tuberculosis (DR-TB) has evolved substantially.Complex, injectable, and highly toxic regimens have largely been replaced by simplified, oral, weight-based fixed-dose combinations for DS-TB and shorter, all-oral regimens for DR-TB.These advances have significantly improved the feasibility and programmatic implementation.However, standardized dosing frameworks have been developed primarily for operational simplicity and assume pharmacokinetic uniformity across diverse patient populations.Despite guideline-concordant drug selection, dosing, and duration, a significant proportion of patients experience delayed response, treatment failure, relapse, or drug-related toxicity.These outcomes often prompt prolonged treatment duration, empirical regimen escalation, or unnecessary exposure to additional drugs and adverse effects.A major but under recognized contributor to these suboptimal outcomes is interindividual variability in drug exposure, resulting in pharmacokinetically inappropriateboth low and high-antitubercular drug concentrations.Therapeutic drug monitoring (TDM) offers a pragmatic approach to optimizing antitubercular therapy (ATT) by linking drug exposure to clinical response and toxicity.Despite being a clinical tool, TDM is frequently perceived as experimental or laboratory-centric and therefore remains underutilized in routine pulmonary practice.

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Antibiotics Pharmacokinetics and Efficacy Pharmacogenetics and Drug Metabolism

Publication details

Journal / source
Journal of PACS
Volume
2
Issue
1
Pages
45–47
Publication date
31 March 2026
Language
EN